A Flow Cytometric Study of Reagent Cells to Resolve ABO Typing Discrepancy

e-protein
November 4, 2020 0 Comments

A Flow Cytometric Study of Reagent Cells to Resolve ABO Typing Discrepancy

Objectives: RBC alloantibodies can lead to ABO grouping discrepancies unrelated to A or B antigens or antibodies posing challenges within the blood financial institution testing. Routine blood financial institution testing and circulation cytometry have been used to immunophenotype reagent cells and elucidate the reason for ABO discrepancies in two sufferers.

Methods: ABO discrepancy was recognized in two sufferers after transfusion with a number of models of RBCs. For each sufferers, the pretransfusion kind and display demonstrated blood group A. Eight and 16 days later, each sufferers confirmed an obvious antibody to reagent group A cells, which prompted extra examine with sufferers’ samples and circulation cytometric testing of business reagent cells. read more

Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays

e-protein
November 4, 2020 0 Comments

Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays utilizing totally different reagents: Results of a UK NEQAS proficiency testing train

Introduction: Emicizumab (Hemlibra: Roche Switzerland) is a, humanized, bi-specific monoclonal modified immunoglobulin G4 (IgG4) which binds human FX, FIX and activated FIX (FIXa) to imitate activated FVIII exercise.

Aim: Evaluate the consequences of emicizumab on the APTT, surrogate FVIII exercise and FVIII inhibitor outcomes.

Methods: Two samples had been supplied, one obtained from an emicizumab handled extreme haemophilia A affected person with FVIII inhibitors and one constructed by in vitro addition of emicizumab utilizing plasma from a extreme haemophilia A affected person with out FVIII inhibitors. An APTT display, surrogate FVIII and FVIII inhibitor assessments had been carried out on each samples by collaborating centres. read more

A Difluoroalkylation Reagent for Organocatalytic Vinylogous Nitroaldol

e-protein
November 4, 2020 0 Comments

A spot check for willpower of residual TBA ranges in  F-radiotracers for human use utilizing Dragendorff reagent

 

When using [18F]tetrabutylammonium fluoride ([18F]TBAF) within the synthesis of 18F-labeled radiotracers for scientific positron emission tomography (PET) imaging, it’s essential to substantiate that residual TBA ranges in formulated doses don’t exceed established specs (≤2.6 mg per affected person dose).

Historically this has been completed utilizing HPLC, however that is time consuming for short-lived PET radiotracers and restricted by the necessity for costly gear. This motivated us to introduce a TLC spot check for figuring out residual TBA, and we’ve got developed a brand new methodology which employs the Dragendorff reagent. Herein we report particulars of the TLC methodology and use it to quantify residual TBA in several formulations of 6-[18F]fluoro-DOPA. read more